DOCSLIB.ORG

Quantitation of Evs in Human Plasma: Applying the Exoview® Tetraspanin Assay in a Physiologically Relevant System

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantitation of Evs in Human Plasma: Applying the Exoview® Tetraspanin Assay in a Physiologically Relevant System Quantitation of EVs in Human Plasma: Applying the ExoView® Tetraspanin Assay in a Physiologically Relevant System The ExoView® Tetraspanin Assay uses human tetraspanin antibodies arrayed on a chip to capture specific extracellular vesicles (EVs) that are detected using specific antibodies conjugated to fluorescent readouts. The data from 3 fluorescent channels and UV-based interferometric images are analyzed to identify the number, size and composition of specific EVs. The ExoView assay chips can be customized to bind custom surface markers. One application is the detection and quantitation of Tspan8 (Tetraspanin 8) positive EVs in plasma. Tspan8 is a biomarker associated with carcinomas such as pancreatic cancer, therefore assaying the number of Tspan8 positive EVs in patient blood samples would be of great clinical importance for therapeutic monitoring and disease diagnostics. Tspan8 positive EVs are present at very low concentrations, so it is necessary to use an assay with high levels of sensitivity and specificity. ASSAY SENSITIVITY Complete conditioned media from HEK293 cells were assayed to determine the concentration range of EV detection. The slope of the EV count vs. dilution was linear down to the lowest concentration tested, 1:25600. Based on an NTA concentration of 3.5x1010 EVs/mL, the limit of detection is less than or equal to 1.37x106 EVs/ mL in the ExoView assay. Given that the assay saturated at a 1:100 dilution of complete conditioned media, the upper concentration range of the ExoView assay in this experiment was 3.5x108 EVs/mL or 2.4 log linear range. Other samples tested (data not shown) show EVs detectable from 1.37x106 EVs/mL to 1x109 EVs/mL or 2.8 log detection range. 10000 HEK293T Complete Medium R2=0.99 8000 CD63 R2=0.99 6000 CD9 CD81 4000 EV Count R2=0.99 2000 0 0.000 0.002 0.004 0.006 0.008 0.010 Dilution The ExoView assay has a lower limit of detection of approximately 1.4x106 EVs/ml - about 10X more sensitive than other assays. 1 NanoView Biosciences, Boston MA For Research Use Only +1-781-365-8439 [email protected] ASSAY SPECIFICITY Three media samples from cultured HEK293 cells were concentrated 45x by UCF before being experimentally tested: • Basal: Conditioned medium without FBS that includes EVs from cells • Complete: Conditioned medium with exosome depleted FBS that contain EVs from cells and serum proteins • Complete NC: Unconditioned medium containing serum (i.e. no cell culture EVs) ExoView NTA Fluorocet Bradford Assay 8 x 10 11 6x10 11 4 x 10 11 2x10 11 0 The Bradford and Fluorocet assays nonspecifically detect proteins in serum containing media while the ExoView assays specifically detect EVs from conditioned serum-free media or media with exosome depleted serum. A clinically relevant application of the TSPAN8 ExoView assay is the detection of disease- A CD9 specific EVs in patient plasma with a high degree of specificity and sensitivity. The ExoView assay was used to determine if a specific EV subpopulation can be CD9 specifically measured when spiked into human plasma at low concentrations. • CD9 positive EVs that are TSPAN8 B counterstained using a Tspan8 antibody CD9 show the expected linear concentration curve. CD63 • EVs captured using Tspan8 on the ExoView TSPAN8 chip show concentration-dependent detection of CD9, CD63 and Tspan8, in fluorescence counterstaining. The ExoView assay offers sensitive and specific detection of EV sub populations and has flexible configurations for capture and detection methods. 2 NanoView Biosciences, Boston MA For Research Use Only +1-781-365-8439 [email protected].
Load more

Recommended publications
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Identification of Key Pathways and Genes in Dementia Via Integrated Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2021.04.18.440371; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification of Key Pathways and Genes in Dementia via Integrated Bioinformatics Analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karnataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2021.04.18.440371; this version posted July 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract To provide a better understanding of dementia at the molecular level, this study aimed to identify the genes and key pathways associated with dementia by using integrated bioinformatics analysis. Based on the expression profiling by high throughput sequencing dataset GSE153960 derived from the Gene Expression Omnibus (GEO), the differentially expressed genes (DEGs) between patients with dementia and healthy controls were identified. With DEGs, we performed a series of functional enrichment analyses. Then, a protein–protein interaction (PPI) network, modules, miRNA-hub gene regulatory network and TF-hub gene regulatory network was constructed, analyzed and visualized, with which the hub genes miRNAs and TFs nodes were screened out. Finally, validation of hub genes was performed by using receiver operating characteristic curve (ROC) analysis.
    [Show full text]
  • Downloaded 18 July 2014 with a 1% False Discovery Rate (FDR)
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer Permalink https://escholarship.org/uc/item/0t47b9ws Author Spiciarich, David Publication Date 2017 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Chemistry in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Professor Matthew B. Francis Professor Amy E. Herr Fall 2017 Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer © 2017 by David Spiciarich Abstract Chemical glycoproteomics for identification and discovery of glycoprotein alterations in human cancer by David Spiciarich Doctor of Philosophy in Chemistry University of California, Berkeley Professor Carolyn R. Bertozzi, Co-Chair Professor David E. Wemmer, Co-Chair Changes in glycosylation have long been appreciated to be part of the cancer phenotype; sialylated glycans are found at elevated levels on many types of cancer and have been implicated in disease progression. However, the specific glycoproteins that contribute to cell surface sialylation are not well characterized, specifically in bona fide human cancer. Metabolic and bioorthogonal labeling methods have previously enabled enrichment and identification of sialoglycoproteins from cultured cells and model organisms. The goal of this work was to develop technologies that can be used for detecting changes in glycoproteins in clinical models of human cancer.
    [Show full text]
  • Human Induced Pluripotent Stem Cell–Derived Podocytes Mature Into Vascularized Glomeruli Upon Experimental Transplantation
    BASIC RESEARCH www.jasn.org Human Induced Pluripotent Stem Cell–Derived Podocytes Mature into Vascularized Glomeruli upon Experimental Transplantation † Sazia Sharmin,* Atsuhiro Taguchi,* Yusuke Kaku,* Yasuhiro Yoshimura,* Tomoko Ohmori,* ‡ † ‡ Tetsushi Sakuma, Masashi Mukoyama, Takashi Yamamoto, Hidetake Kurihara,§ and | Ryuichi Nishinakamura* *Department of Kidney Development, Institute of Molecular Embryology and Genetics, and †Department of Nephrology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; ‡Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima University, Hiroshima, Japan; §Division of Anatomy, Juntendo University School of Medicine, Tokyo, Japan; and |Japan Science and Technology Agency, CREST, Kumamoto, Japan ABSTRACT Glomerular podocytes express proteins, such as nephrin, that constitute the slit diaphragm, thereby contributing to the filtration process in the kidney. Glomerular development has been analyzed mainly in mice, whereas analysis of human kidney development has been minimal because of limited access to embryonic kidneys. We previously reported the induction of three-dimensional primordial glomeruli from human induced pluripotent stem (iPS) cells. Here, using transcription activator–like effector nuclease-mediated homologous recombination, we generated human iPS cell lines that express green fluorescent protein (GFP) in the NPHS1 locus, which encodes nephrin, and we show that GFP expression facilitated accurate visualization of nephrin-positive podocyte formation in
    [Show full text]
  • Molecular Bases of Equine Polysaccharide Storage Myopathies a Dissertation SUBMITTED to the FACULTY of UNIVERSITY of MINNESOTA
    Molecular bases of equine polysaccharide storage myopathies A Dissertation SUBMITTED TO THE FACULTY OF UNIVERSITY OF MINNESOTA BY Raffaella Bertoni Cavalcanti Teixeira IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Molly McCue, James Mickelson April, 2015 © {Raffaella Bertoni Cavalcanti Teixeira, 2015} Acknowledgements First of all I am thankful to Drs McCue and Mickelson for their essential support. Without their superior knowledge and experience I would not have been able to accomplish this work. The author would also like to thank Drs Reed, Rendahl and Valberg for being part of my committee and for their support and help. I would also like to acknowledge Rob Schaefer for all his help with scripts and commands. I have learned a lot from him. I would like to thank my lab mates Sam Beeson, Elaine Norton, Annette McCoy, Felipe Avila, Nichol Schultz and Ann Kemper for their help and friendship. And last, I want to thank my dog Stella for showing me her love during good and bad times. I have met incredible people during this journey and I’m very thankful to each one of them. You have all left a mark on my life forever. i Dedication This thesis is dedicated to my adviser Dr McCue for helping me achieve my goal of completing a PhD. Dr McCue has taught me so many important lessons. I’m a better scientist, clinician and most of all, a better person because of her. Her lessons will stay with me for the rest of my life. I also dedicate this work to my co-adviser, Dr Mickelson, for being supportive, helpful, wise and very patient.
    [Show full text]
  • The Expression of Genes Contributing to Pancreatic Adenocarcinoma Progression Is Influenced by the Respective Environment – Sagini Et Al
    The expression of genes contributing to pancreatic adenocarcinoma progression is influenced by the respective environment – Sagini et al Supplementary Figure 1: Target genes regulated by TGM2. Figure represents 24 genes regulated by TGM2, which were obtained from Ingenuity Pathway Analysis. As indicated, 9 genes (marked red) are down-regulated by TGM2. On the contrary, 15 genes (marked red) are up-regulated by TGM2. Supplementary Table 1: Functional annotations of genes from Suit2-007 cells growing in pancreatic environment Categoriesa Diseases or p-Valuec Predicted Activation Number of genesf Functions activationd Z-scoree Annotationb Cell movement Cell movement 1,56E-11 increased 2,199 LAMB3, CEACAM6, CCL20, AGR2, MUC1, CXCL1, LAMA3, LCN2, COL17A1, CXCL8, AIF1, MMP7, CEMIP, JUP, SOD2, S100A4, PDGFA, NDRG1, SGK1, IGFBP3, DDR1, IL1A, CDKN1A, NREP, SEMA3E SERPINA3, SDC4, ALPP, CX3CL1, NFKBIA, ANXA3, CDH1, CDCP1, CRYAB, TUBB2B, FOXQ1, SLPI, F3, GRINA, ITGA2, ARPIN/C15orf38- AP3S2, SPTLC1, IL10, TSC22D3, LAMC2, TCAF1, CDH3, MX1, LEP, ZC3H12A, PMP22, IL32, FAM83H, EFNA1, PATJ, CEBPB, SERPINA5, PTK6, EPHB6, JUND, TNFSF14, ERBB3, TNFRSF25, FCAR, CXCL16, HLA-A, CEACAM1, FAT1, AHR, CSF2RA, CLDN7, MAPK13, FERMT1, TCAF2, MST1R, CD99, PTP4A2, PHLDA1, DEFB1, RHOB, TNFSF15, CD44, CSF2, SERPINB5, TGM2, SRC, ITGA6, TNC, HNRNPA2B1, RHOD, SKI, KISS1, TACSTD2, GNAI2, CXCL2, NFKB2, TAGLN2, TNF, CD74, PTPRK, STAT3, ARHGAP21, VEGFA, MYH9, SAA1, F11R, PDCD4, IQGAP1, DCN, MAPK8IP3, STC1, ADAM15, LTBP2, HOOK1, CST3, EPHA1, TIMP2, LPAR2, CORO1A, CLDN3, MYO1C,
    [Show full text]
  • Immunotherapy of Colorectal Cancer
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 13), pp: 22034-22047 Research Paper Tetraspanin 8 (TSPAN 8) as a potential target for radio- immunotherapy of colorectal cancer Aurelie Maisonial-Besset1,2,*,**, Tiffany Witkowski1,2,*,**, Isabelle Navarro-Teulon3,4,5, Odile Berthier-Vergnes6,7, Giovanna Fois2,8, Yingying Zhu9,10,11, Sophie Besse1,2, Olivia Bawa12, Arnaud Briat1,2, Mercedes Quintana1,2, Alexandre Pichard3,4,5, Mathilde Bonnet2,13, Eric Rubinstein9,10,11, Jean-Pierre Pouget3,4,5, Paule Opolon12, Lydia Maigne2,8, Elisabeth Miot-Noirault1,2, Jean-Michel Chezal1,2, Claude Boucheix9,10,11,*, Françoise Degoul1,2,* 1INSERM, U 1240, Clermont-Ferrand, France 2Université Clermont Auvergne, Imagerie Moléculaire et Thérapie Vectorisée, Clermont-Ferrand, France 3IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France 4INSERM, U896, Montpellier, France 5Université Montpellier 1, Montpellier, France 6Université de Lyon 1, Lyon, France 7CNRS, UMR5534, Centre de Génétique et de Physiologie Moléculaires et Cellulaires, Villeurbanne, France 8CNRS/IN2P3, UMR6533, Laboratoire de Physique Corpusculaire (LPC), Clermont-Ferrand, France 9INSERM, UMR-S 935, Villejuif, France 10Université Paris-Sud 11, Orsay, France, 11Université Paris Saclay, Saint-Aubin, France, 12Gustave Roussy, Laboratoire de Pathologie Expérimentale, Villejuif, France 13INSERM U1071, Faculté de Médecine, Clermont Ferrand, France *These authors have contributed equally to this work **First co-authors Correspondence to: Françoise Degoul, email: [email protected] Keywords: TSPAN8, radioimmunotherapy, colorectal cancer, dosimetry Abbreviations: DOTA: 2,2’,2’’-(10-(2-((2,5-dioxopyrrolidin-1-yl)oxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid Received: December 12, 2016 Accepted: January 24, 2017 Published: February 28, 2017 ABSTRACT Tetraspanin 8 (TSPAN8) overexpression is correlated with poor prognosis in human colorectal cancer (CRC).
    [Show full text]
  • Studying the Impact of Tspan8 on Extracellular Vesicles in Breast Cancer and Application of a Novel Tool for Their Detection
    Studying the impact of Tspan8 on extracellular vesicles in breast cancer and application of a novel tool for their detection Inaugural-Dissertation zur Erlangung der Doktorwürde der Fakultät für Biologie der Albert-Ludwigs-Universität Freiburg im Breisgau Vorgelegt von Richa Khanduri geboren in Delhi, Indien Freiburg im Breisgau Dezember 2018 Die vorliegende Arbeit entstand in der Arbeitsgruppe Exosomen und Tumorbiologie des Instituts für Infektionsprävention und Krankenhaushygiene am Universitätsklinikum Freiburg unter der Anleitung von PD Dr. Irina Nazarenko. Dekan der Fakultät für Biologie: Prof. Dr. Wolfgang Driever Promotionsvorsitzender: Prof. Dr. Andreas Hiltbrunner Betreuerin der Arbeit: PD Dr. Irina Nazarenko Betreuerin der Fakultät für Biologie: Prof. Dr. Annegret Wilde Referentin: Prof. Dr. Annegret Wilde Koreferent: Prof. Dr. Thomas Reinheckel Drittprüfer: Prof. Dr. Dr. h.c. Christoph Borner Datum der mündlichen Prüfung: 25.02.2019 i DECLARATION I hereby declare, that I am the sole author and composer of my Thesis and that no other sources or learning aids, other than those listed, have been used. Furthermore, I declare that I have acknowledged the work of others by providing detailed references of said work. I hereby also declare, that my Thesis has not been prepared for another examination or assignment, either wholly or excerpts thereof. Freiburg, 28.02.2019 ___________________________________ Place, date Signature Richa Khanduri ii Life consists in penetrating the unknown and fashioning our actions in accord with the new
    [Show full text]
  • Chapter 14: Genetics of Type 2 Diabetes
    CHAPTER 14 GENETICS OF TYPE 2 DIABETES Jose C. Florez, MD, PhD, Miriam S. Udler, MD, PhD, and Robert L. Hanson, MD, MPH Dr. Jose C. Florez is Chief of the Diabetes Unit and an investigator in the Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, and Co-Director of the Program in Metabolism and Institute Member in the Broad Institute, Cambridge, MA, and Associate Professor in the Department of Medicine, Harvard Medical School, Boston, MA. Dr. Miriam S. Udler is Clinical Fellow in the Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, and Postdoctoral Fellow in the Programs in Metabolism and Medical & Population Genetics, Broad Institute, Cambridge, MA, and Research Fellow in the Department of Medicine, Harvard Medical School, Boston, MA. Dr. Robert L. Hanson is Clinical Investigator and Head, Genetic Epidemiology and Statistics Unit in the Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ. SUMMARY Type 2 diabetes is thought to result from a has been found to have a stronger effect insufficient sample sizes to detect small combination of environmental, behavioral, than the rs7903146 SNP in TCF7L2, which effects, a nearly exclusive focus on popu- and genetic factors, with the heritability itself has only a modest effect (odds ratio lations of European descent, an imperfect of type 2 diabetes estimated to be in the ~1.4). Nonetheless, GWAS findings have capture of uncommon genetic variants, range of 25% to 72% based on family and illustrated novel pathways, pointed toward an incomplete ascertainment of alternate twin studies.
    [Show full text]
  • Quantifying and Phenotyping Extracellular Vesicles
    Quantifying and Phenotyping Extracellular Vesicles Sensitivity and Specificity of the ExoView® Tetraspanin Assay WHITE PAPER THEMES: • ExoView® Assay Sensitivity Using HEK293 and AsPC1 Cells • Comparative Analysis of Assay Specificity • Detection of EVs in Physiologically Relevant Plasma Introduction Quantifying extracellular vesicle (EV) biomarkers The ExoView® Tetraspanin Assay from NanoView in unpurified or unprocessed samples is of key Biosciences provides data for single EVs and is importance in several scenarios. For example, based on specific EV capture by human or mouse companies that are developing EV-based tetraspanin antibodies arrayed on a chip. therapeutics must ensure lot-to-lot consistency of their product and any engineered cargo. In clinical Data from three fluorescent channels and research, EVs derived from specific tissues UV-based interferometric (IM) images are or tumors can contain important circulating or collected in an automated workflow using the excreted biomarkers, but the population of interest ExoView R100 instrument. Thousands of EVs is likely to be rare (perhaps less than 1%)1. are quantified to determine size and surface/ cargo marker colocalization in a single assay. Due to their small size and low protein content, Standard ExoView chips include tetraspanin EVs are challenging to quantify and phenotype. markers suitable for measuring EVs from cell Many technologies and assays are currently in culture (Tetra-C) and plasma (Tetra-P). Chips use based on various features of EVs, including can also be customized to bind custom surface nanoparticle tracking, total protein content, and markers, for example, in this paper we show acetylcholinesterase activity. However, these that Tetraspanin8 (Tspan 8) positive EVs in assays are non-specific and detect non-vesicular plasma can be captured and quantified.
    [Show full text]
  • TLR4 Regulation in Human Fetal Membranes As an Explicative Mechanism of A
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.28.450131; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 1 TLR4 regulation in human fetal membranes as an explicative mechanism of a 2 pathological preterm case. 1 1 1 1 3 Corinne Belville , Flora Ponelle-Chachuat , Marion Rouzaire , Christelle Gross , Bruno 4 Pereira2, Denis Gallot1, 3, Vincent Sapin1, 4, Loïc Blanchon1,. 5 6 Author affiliation: 7 1. Team “Translational approach to epithelial injury and repair,” GReD, Université Clermont 8 Auvergne, UMR6293 CNRS-U1103 INSERM, F-63000 Clermont-Ferrand, France. 9 2. CHU Clermont-Ferrand, Biostatistics unit (DRCI) Department, F-63000 Clermont-Ferrand, 10 France. 11 3. CHU Clermont-Ferrand, Obstetrics and Gynecology Department, F-63000 Clermont- 12 Ferrand, France. 13 4. CHU Clermont-Ferrand, Biochemistry and Molecular Genetic Department, F-63000 14 Clermont-Ferrand, France. 15 16 Corresponding author: Dr Loic Blanchon, UFR de Médecine et des Professions 17 Paramédicales, Bâtiment CRBC, GReD, TSA 50400, 28 place Henri-Dunant, F63001 18 Clermont-Ferrand Cedex 1, France, Tel: +33 4 73 17 81 74, e-mail: [email protected] 19 Short Title: TLR4 control upon fetal membrane rupture 20 21 Keywords: fetal membranes rupture / methylome / miRNA / transcriptome / TLR4 22 23 Word count: Abstract: 179 24 bioRxiv preprint doi: https://doi.org/10.1101/2021.06.28.450131; this version posted July 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]